Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Iqvia. (4/30/18). "Press Release: Recordati Selects Iqvia’s OCE Technology Platform and OneKey Information Services". Danbury, CT & Research Triangle Park, NC.

Organisations Organisation Iqvia (NYSE: IQV)
  Group Iqvia (Group)
  Organisation 2 Recordati Industria Chimica e Farmaceutica S.p.A.
  Group Recordati (Group)
Products Product information services
  Product 2 pharmaceutical
Person Person Recordati, Andrea (Recordati 201309– COO)
     


Novel combination connects commercial functions and preferred customer channels with comprehensive information on healthcare professionals and organizations


IQVIA (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, and Recordati SpA today announced a service alliance. Under the agreement Recordati will deploy IQVIA’s commercial technology solution, Orchestrated Customer Engagement (OCE) with OneKey, a comprehensive source of reference information on healthcare organizations and professionals (HCPs).

OCE’s commercial technology platform enables life sciences companies to transform customer engagement. OCE connects clients’ marketing, sales and other functions to integrate customer interactions, building trust and optimizing performance. By leveraging OneKey – which delivers comprehensive, accurate HCP information across 100 countries and is connected to IQVIA’s sales, medical claims, prescriptions, procedures and diagnosis information – OCE provides an unprecedented commercial experience.

Under the terms of this seven-year agreement, Recordati will move current CRM users to OCE, which Recordati selected because of its strong “platform of platforms” foundation and open architecture. Recordati will also benefit from greater control of HCP interaction using OneKey, which provides insight into more than 15 million professionals and one million healthcare organizations as well as the groups linking them together. This unique combination will be rolled out in a total of 17 countries with potential for further expansion into other countries where Recordati operates.

“This partnership with IQVIA is an important step forward for us to drive our customer-centric strategy across our business and continue our global expansion,” said Andrea Recordati, CEO at Recordati SpA.

IQVIA’s OCE solution is built on best-in-class technologies such as Salesforce.com, Mulesoft, Amazon Web Services, Heroku, Box and others to provide seamless use across a “platform of platforms.” The solution runs on Ada™, artificial intelligence that gives recommendations for next-best actions; Apollo™, an intuitive user interface; and Lexi™, an application program interface layer to connect all applications and data using common language.

“We are pleased that Recordati will deploy our new OCE technology with our robust OneKey dataset,” said Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA. “The OCE and OneKey combination will give Recordati greater understanding of its customers and markets through richer professional and organizational information, new data sources, expanded coverage, and timely updates across our nimble platform of platforms technology.”

IQVIA is committed to developing innovative technology solutions that help life sciences converge functional silos, integrate processes, strengthen customer relationships, and more effectively anticipate and respond to market changes. Additional information about OCE is available on the IQVIA website.


About Recordati SpA

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America, in Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.


About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.

Click here to subscribe to Mobile Alerts for IQVIA.


Contacts

IQVIA Media Relations
Tor Constantino, +1-484-567-6732
tor.constantino@iqvia.com

or

IQVIA Investor Relations
Andrew Markwick, +1-973-257-7144
andrew.markwick@iqvia.com

   
Record changed: 2018-05-09

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Iqvia (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top